A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Estado	**Tipo de Participantes**	**Rangos de Edad**
Reclutando	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase I , Fase II	354
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	No
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	tratamiento, seguridad, eficacia, farmacocinética, farmacodinamica, dosis, farmacogenómica	NO

Información

Identificador

2024-516289-12-00 (CTIS)

Cod. Protocolo

CYC065-101

Transicionado 2021-002924-18

Área terapéutica

Enfermedades [C] - Cáncer [C04]|

Enfermedad investigada

Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer (metastatic HER-2 refractory, Hormone receptor +, HER-2 negative, and MBC post-CDK4/6 inhibitor, Triple-negative) Basket cohort: tumor types that are suspected to have a related mechanism of action and are not included in previous groups

Título Científico

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

Justificación

No aportado

Objetivo Principal

Phase 1:
To determine the maximum-tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of fadraciclib when administered orally twice daily (BID) or once daily (QD) in 28-day cycles in adult subjects with advanced solid tumors and lymphoma
Phase 2:
To evaluate preliminary efficacy of fadraciclib as measured by overall response rate (ORR) in subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma who have failed all standard therapies or for whom standard therapy does not exist

Variables de Evaluación Primaria

Phase 1: The incidence rate of dose-limiting toxicities (first cycle only) at each dose level. Phase 2: ORR according to Response Evaluation Criteria in Solid Tumors: RECIST guidelines (Lugano Criteria for lymphoma, mSWAT for CTCL) for each tumor type

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Phase 1: - To assess safety and tolerability of fadraciclib - To investigate clinical pharmacokinetics (PK) of fadraciclib - To evaluate overall response rate (ORR) in subjects receiving fadraciclib Phase 2: - To assess the safety and tolerability of fadraciclib - To evaluate the disease control rate (DCR), duration of response (DOR), progression free survival (PFS), and overall survival (OS), in subjects receiving fadraciclib

Variables de Evaluación Secundaria

Safety
Disease control rate (DCR)
Response rate as per Lugano Criteria for lymphoma, mSWAT for CTCL

Progression-free survival
Duration of response
Overall survival
PK in Phase 1

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Males or females aged 18 years or per local regulatory guidelines
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
ECOG performance status of 0 or 1
Subjects must have laboratory values as stated in the protocol
Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
Able to agree to and sign the informed consent and to comply with the protocol.

Criterios de Exclusión

Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV). In subjects with a history of HBV, hepatitis B core antibody testing is required and if positive, then HBV DNA testing will be performed, and if positive, the subject will be excluded. For subjects with HCV Ab positive, HCV viral load must be below the limit of quantification.
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy. Patients on a stable dose os fulvestrant prior to enrollment may continue to receive fulvestrant.
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
Subjects who have not received vaccines for SARS-COV-2 and have suspected signs and symptoms of COVID-19 or have confirmed COVID- 19.
Subjects with a history of another primary malignancy, please see additional details in the protocol.
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results. See additional details in the protocol.
Diseases that significantly affect GI absorption of fadraciclib
Subjects who have impaired cardiac function or clinically significant cardiac disease, see additional details in the protocol.
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
Presence of an active infection requiring intravenous antibiotics

Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism

Calendario

(Última actualización: 23/04/2025)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
08/10/2021	24/02/2022	28/02/2022	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
No aportado	No aportado	No aportado	No aportado	No aportado

Promotor

Cyclacel Limited United Kingdom

2 London Wall Place

Contact Person

Khan Maola

16176423886

mkhan@cyclacel.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Centros

Cerrado (26/02/2025)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Oncology

Medicamentos

PRD9757764

TABLET

ORAL USE

-

Principios Activos: N/A

Experimental

Sin resultados

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

State	**Type of participants**	**Age Ranges**
Recruiting	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase I , Phase II	354
Results	**Low level of intervention**	**Rare disease**
No results	No	No
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	treatment, safety, effectiveness, pharmacokinetics, pharmacodynamics, dose, pharmacogenomics	NO

Information

Identifier
2024-516289-12-00 (CTIS)

Protocol Code
CYC065-101

Transitioned 2021-002924-18

Therapeutic area
Diseases [C] - Cancer [C04]|

Investigated Disease
Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer (metastatic HER-2 refractory, Hormone receptor +, HER-2 negative, and MBC post-CDK4/6 inhibitor, Triple-negative) Basket cohort: tumor types that are suspected to have a related mechanism of action and are not included in previous groups

Scientific Title

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

Rationale

Not provided

Main Objective

Phase 1:
To determine the maximum-tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of fadraciclib when administered orally twice daily (BID) or once daily (QD) in 28-day cycles in adult subjects with advanced solid tumors and lymphoma
Phase 2:
To evaluate preliminary efficacy of fadraciclib as measured by overall response rate (ORR) in subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma who have failed all standard therapies or for whom standard therapy does not exist

Primary Endpoints

Phase 1: The incidence rate of dose-limiting toxicities (first cycle only) at each dose level. Phase 2: ORR according to Response Evaluation Criteria in Solid Tumors: RECIST guidelines (Lugano Criteria for lymphoma, mSWAT for CTCL) for each tumor type

Temporary moments of secondary assessment

Not provided

Secondary Objective

Phase 1: - To assess safety and tolerability of fadraciclib - To investigate clinical pharmacokinetics (PK) of fadraciclib - To evaluate overall response rate (ORR) in subjects receiving fadraciclib Phase 2: - To assess the safety and tolerability of fadraciclib - To evaluate the disease control rate (DCR), duration of response (DOR), progression free survival (PFS), and overall survival (OS), in subjects receiving fadraciclib

Secondary Endpoints

Safety
Disease control rate (DCR)
Response rate as per Lugano Criteria for lymphoma, mSWAT for CTCL

Progression-free survival
Duration of response
Overall survival
PK in Phase 1

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Males or females aged 18 years or per local regulatory guidelines
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
ECOG performance status of 0 or 1
Subjects must have laboratory values as stated in the protocol
Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
Able to agree to and sign the informed consent and to comply with the protocol.

Exclusion criteria

Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV). In subjects with a history of HBV, hepatitis B core antibody testing is required and if positive, then HBV DNA testing will be performed, and if positive, the subject will be excluded. For subjects with HCV Ab positive, HCV viral load must be below the limit of quantification.
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy. Patients on a stable dose os fulvestrant prior to enrollment may continue to receive fulvestrant.
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
Subjects who have not received vaccines for SARS-COV-2 and have suspected signs and symptoms of COVID-19 or have confirmed COVID- 19.
Subjects with a history of another primary malignancy, please see additional details in the protocol.
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results. See additional details in the protocol.
Diseases that significantly affect GI absorption of fadraciclib
Subjects who have impaired cardiac function or clinically significant cardiac disease, see additional details in the protocol.
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
Presence of an active infection requiring intravenous antibiotics

Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism

Calendar

(Last Update: 23/04/2025)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
08/10/2021	24/02/2022	28/02/2022	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
Not aported	Not aported	Not aported	Not aported	Not aported

Sponsor

Cyclacel Limited United Kingdom

2 London Wall Place

Contact Person

Khan Maola

16176423886

mkhan@cyclacel.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Universitari Vall d Hebron

Passeig de la Vall d.Hebron, 119-129 - Edificio Materno-Infantil, planta 13 08035 Barcelona

ceic@vhir.org

934894010

Sites

Closed (26/02/2025)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Oncology

Medication

PRD9757764

TABLET

ORAL USE

-

Active Principles: N/A

Experimental

No results